To get federal regulators off snail-paced Washington time and up to Silicon Valley speed, the FDA’s Dr. Bakul Patel is creating a new unit dedicated to digital health, according to an article posted on the Wired website.
President Donald Trump’s first major budget proposal, scheduled for Tuesday, May 22, will include massive cuts to Medicaid and will give states new power to limit a range of benefits despite growing unease in Congress, according to an article in the Washington Post.
President Trump plans to cut spending on Medicaid by more than $800 billion over the next 10 years, the Washington Post reports. The plan, considered the administration’s first major budget proposal, is expected to be released tomorrow.
Amazon, which seems to be taking over everything, has set it sights on becoming a pharmacy benefit manager (PBM). CNBC reports that the online retailer—you know, the site where you can buy practically anything—is exploring how to become a PBM. This is interesting.
Tony Durmowicz, MD, and Mike Pacanowski, PharmD, MPH, both from the FDA’s Center for Drug Evaluation and Research (CDER), have written a “Spotlight on CDER Science” article that considers the implications of the recent expansion of the indications for ivacaftor (Kalydeco, Vertex Pharmaceuticals), which was based on in vitro assay data rather than
Use of the erectile dysfunction drug sildenafil citrate (Viagra, Pfizer) does not cause the development of melanoma, a deadly form of skin cancer, according to the main finding of new research led by investigators at NYU Langone Medical Center and its Perlmutter Cancer Center and published online in the Journal of the National Cancer Institute.
After analyzing the blood of a survivor of the 2013–2016 Ebola outbreak, a team of scientists from academia, industry, and the government has discovered the first natural human antibodies that can neutralize and protect animals against all three major disease-causing ebolaviruses.
More than a dozen Democratic attorneys general sought Thursday to intervene to defend a key part of the Patient Protection and Affordable Care Act (PPACA)—subsidy payments to insurance companies—that is under threat in a court case.
A new study shows that the number of women in the United States living with distant metastatic breast cancer (MBC), the most severe form of the disease, is growing. This is likely due to the aging of the U.S. population and improvements in treatment. Researchers came to this finding by estimating the number of U.S.
Positive topline phase 3 results have been reported for the HELP study, a global, multicenter, randomized, double-blind placebo-controlled, parallel-group trial that evaluated the efficacy and safety of subcutaneously administered lanadelumab (Shire) versus placebo over 26 weeks in patients 12 years of age or older with hereditary angioedema (HAE).
Some of the world’s largest funders of medical research and international non-governmental organizations (NGOs) have agreed on new standards that will require all clinical trials they fund or support to be registered, and the results disclosed publicly.
The FDA has expanded the approved use of ivacaftor (Kalydeco, Vertex Pharmaceuticals) for treating cystic fibrosis. The approval triples the number of rare gene mutations that the drug can now treat, expanding the indication from the treatment of 10 mutations to 33.
Positive results from a post-hoc analysis of data from the phase 3a Satiety and Clinical Adiposity–Liraglutide Evidence (SCALE) maintenance trial were recently presented at the 24th European Congress on Obesity.
A study at the University of Nebraska Medical Center (UNMC) found that a novel device can significantly reduce contamination of blood cultures, potentially reducing risky overtreatment and unnecessary use of antibiotics for many patients. This approach could also substantially reduce health care costs, according to the study.